Of note, growth inhibition in BRAFi-R melanoma cells treated with hi-dose or low-dose PLX4032 was increased following corin treatment versus treatment with the LSD1 inhibitor Cpd7 or the HDAC1 inhibitor MS275 alone, suggesting specific synergies with PXL4032 activity relevant to targeting of the CoREST complex (Figure 3F). Here, RCOR1 is linked to melanoma.